Geron Corporation (GERN)
After hours:
| Previous close | 1.3200 |
| Open | 1.3600 |
| Bid | 1.3000 x 3000 |
| Ask | 1.3900 x 3100 |
| Day's range | 1.2300 - 1.3800 |
| 52-week range | 0.9900 - 2.2300 |
| Volume | |
| Avg. volume | 2,520,508 |
| Market cap | 428.192M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., May 19, 2022--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Business Wire
Geron to Present at the H.C. Wainwright Global Investment Conference
FOSTER CITY, Calif., May 17, 2022--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.
- Business Wire
Geron Corporation Reports First Quarter 2022 Financial Results
FOSTER CITY, Calif., May 09, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.
